Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vincerx Pharma, Inc.
Part 2 VIP152 Monotherapy (Global). Part 3 dose escalation with VIP152 in combination with pembrolizumab (US only). Part 4 dose expansion with VIP152 in combination with pembrolizumab (US only).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part 2 (Global), Part 3 (US Only), and Part 4 (US Only)
Male or female patients aged \>/=18 years
Patients with a histologically or cytologically confirmed solid tumor or aggressive NHL who are refractory to or have exhausted all available therapies with MYC expression or known C-MYC amplification/alterations
Adequate bone marrow, liver, and renal functions
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
In the addition to the above Part 3 (US Only) and Part 4 (US Only)
Must be eligible to use pembrolizumab per USPI
You may not be if
Active clinically serious infections of events \> Grade 2
Subjects who have new or progressive brain or meningeal or spinal metastases.
Anticancer chemotherapy or immunotherapy during the study or within 1 weeks prior to the first dose of study drug
Major surgery or significant trauma within 4 weeks before the first dose of study drug
Allogeneic bone marrow transplant or stem cell rescue within 4 months before first dose of study drug; patients must have completed immunosuppressive therapy before enrollment.
